GARY GOFF: Open Payments
NPI 1629050521 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,989 in 104 payments from 24 companies in 2025. Trend: 2023 $2,079 · 2024 $1,902 · 2025 $1,989
Food & beverage: $1,989
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $374 |
| ABBVIE INC. | 13 | $242 |
| Amgen Inc. | 13 | $180 |
| PFIZER INC. | 8 | $155 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $102 |
| GlaxoSmithKline, LLC. | 4 | $102 |
| Novartis Pharmaceuticals Corporation | 4 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| Insmed, Inc. | 4 | $92 |
| Axsome Therapeutics, Inc. | 4 | $91 |
Products named: FARXIGA, OTEZLA, AIRSUPRA, TRELEGY ELLIPTA, REXULTI, Arikayce, Auvelity, QULIPTA.
Industry payments across TX — which companies pay providers there.
